Suboxone is administered as a sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride in the treatment of opioid dependency. Buprenorphine hydrochloride is a partial mu-opioid receptor agonist and a kappa-opiod receptor antagonist. Naloxone hydrochloride is a mu-opioid receptor antagonist and antagonizes the analgesic, psychotogenic, dysphoric, miotic and other pharmacologic effects of opioid analgesics.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
The OEL monograph for Suboxone is under development.
You can contact us and let us know if you'd like to be notified when this document becomes available.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.